MedTrace Logo

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

NCT00539162 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8000

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.

Conditions

Interventions

BEHAVIORAL

Questionnaire

Questionnaires completed at baseline and during each follow up visit.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Golfers Against Cancer

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Denise Nebgen, MD, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-07-02
Primary Completion
2028-11-30
Completion
2028-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539162 on ClinicalTrials.gov